Patent ID: 6939534
Filing Date: 2005-09-06
Classification: A61K

Abstract:
1. A method for treating or preventing pulmonary hypoplasia in a neonate in need thereof comprising: administering recombinant human epidermal growth factor (rhEGF) to the neonate, comprising delivering to the neonate until 31 weeks of gestational age a dosage of aerosolized EGF in solution that is equivalent to continuous endotracheal aerosolization of a solution containing approximately 6.5 ng/ml rhEGF; when the neonate is 31 weeks of gestational age, increasing the concentration of rhEGF in solution to approximately 12.5 ng/ml; and when the neonate is 35 to 40 weeks of gestational age, decreasing the concentration of rhEGF in solution to approximately 4.5 ng/ml.